The DOI matches its Crossref record; 51 of the 55 references it cites were found in a registry or an index; 1 of the 3 sources its claims cite were checked for support.
Beta-Blocker-Related Atrioventricular Conduction Disorders—A Single Tertiary Referral Center Experience
Open accessAbstract
Background and Objectives: Drug-related bradyarrhythmia is a well-documented major adverse event among beta-blocker users and a potential cause for hospitalization or additional interventions. Whether beta-blocker use is associated with specific bradyarrhythmia presentations, and how this relates to other predisposing factors, is not well known. We aim to evaluate the association between beta-blocker use and the type of atrioventricular (AV) conduction disorder in patients with symptomatic bradycardia. Materials and Methods: We conducted a retrospective cohort study on 596 patients with a primary diagnosis of symptomatic bradyarrhythmia admitted to a single tertiary referral center. Of the cases analyzed, 253 patients were on beta-blocker treatment at presentation and 343 had no bradycardic treatment. We analyzed demographics, clinical and paraclinical parameters in relation to the identified AV conduction disorder. A multivariate regression analysis was performed to explore factors associated with beta-blocker use. Results: Of the 596 patients (mean age 73.9 ± 8.8 years, 49.2% male), 261 (43.8%) had a third-degree AV block, 92 (15.4%) had a second-degree AV block, 128 (21.5%) had slow atrial fibrillation, 93 (15.6%) had sick sinus syndrome and 21 (3.5%) had sinus bradycardia/sinus pauses. Beta-blocker use was associated with the female gender (p < 0.001), emergency admission (p < 0.001), dilated cardiomyopathy (p = 0.003), the lower left ventricular ejection fraction (p = 0.02), mitral stenosis (p = 0.009), chronic kidney disease (p = 0.02), higher potassium levels (p = 0.04) and QRS duration > 120 ms (p = 0.02). Slow atrial fibrillation (OR = 4.2, p < 0.001), sick sinus syndrome (OR = 2.8, p = 0.001) and sinus bradycardia/pauses (OR = 32.9, p < 0.001) were more likely to be associated with beta-blocker use compared to the most common presentation (third-degree AV block), after adjusting for other patient characteristics. Conclusions: Beta-blocker use is more likely to be associated with slow atrial fibrillation, sick sinus syndrome and sinus bradycardia/pauses, compared to a second- or third-degree AV block, after adjusting for other patient factors such as gender, admission type, ECG, comorbidities, cardiac function and lab testing.
Overview
CoChat Summary
TL;DR
This retrospective single-center cohort study of 596 patients with symptomatic bradyarrhythmia found that beta-blocker use was more strongly associated with slow atrial fibrillation, sick sinus syndrome, and sinus bradycardia/sinus pauses than with second- or third-degree AV block. The authors argue this pattern may help distinguish potentially reversible drug-related bradyarrhythmia from conduction disease more likely to require pacing.
Key findings
- Among 596 patients (mean age 73.9 ± 8.8 years; 49.2% male), 253 were on beta-blockers and 343 were not on bradycardic medication.
- Beta-blocker use was associated with slow atrial fibrillation (OR = 4.2, p < 0.0001), sick sinus syndrome (OR = 2.8, p = 0.001), and sinus bradycardia/sinus pauses (OR = 32.9, p < 0.0001), compared with third-degree AV block.
- Second-degree AV block was not associated with beta-blocker use (OR = 0.84, p = 0.56).
- In adjusted analyses, beta-blocker use was also associated with female sex (p < 0.0001), emergency admission (p < 0.0001), dilated cardiomyopathy (p = 0.003), lower LVEF (p = 0.02), mitral stenosis (p = 0.009), chronic kidney disease (p = 0.02), higher potassium (p = 0.04), and QRS duration > 120 ms (p = 0.02).
Methods
- Retrospective cohort study at a single tertiary referral center in Northeast Romania, covering admissions from December 2014 to January 2017.
- Included 596 hospitalized adults with symptomatic bradyarrhythmia/symptomatic AV conduction disorders; excluded patients <18 years, acute coronary syndrome-related conduction disorders, non-beta-blocker bradycardic treatment, recent cardiovascular surgery or interventional procedures, pacing devices, or incomplete key data.
- Compared BB+ (n = 253) versus BB− (n = 343) groups using t-tests/Fisher exact tests and multivariable logistic regression with backward stepwise selection.
Limitations
- The paper states limitations of the retrospective design, the number of cases analyzed, and the specificity of the center.
- It also states that some hospital-record data were incomplete and that type/dose of beta-blocker were susceptible to recall bias.
- Evident from the text: this is a single-center study in one region, so generalizability is limited; the authors also note underrepresentation of some beta-blockers used less often in their region.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
1 Valid · 0 Not valid · 0 Not checked · 34 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“It should also be noted that the average dose for each agent was significantly lower than the maximum therapeutic dose [43,44,45].”
§ Beta-Blocker-Related Atrioventricular Conduction Disorders—A Single Tertiary Referral Center Experience > 4. Discussion
What the sources say
- Not matchedcites [43] Helfand, M., Peterson, K., Christensen, V., Dana, T., and Thakurta, S. (2021, September 11). Drug Class Review: Beta Adrenergic Blockers. Oregon Health & Science University, Available online: https://www.ncbi.nlm.nih.gov/books/NBK47172/pdf/Bookshelf_NBK47172.pdf.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Partly supportedcites [44] Lam, 2018, Role of High-Dose Beta-Blockers in Patients with Heart Failure with Preserved Ejection Fraction and Elevated Heart Rate, Am. J. Med. sourceExperimental — accuracy not yet measured
The Methods section (“Discharge Use of Beta-Blockers”; page unavailable) reports that only 15%–49% of recipients of each listed agent met the study’s high-dose threshold, supporting the general point that lower doses were common. It does not report average doses for each agent, identify those thresholds as maximum therapeutic doses, or test whether the averages were significantly lower than those maxima. (LLM, conf=0.82)
- Not checked — no full text of the sourcecites [45] Swedberg, 2004, Expert Consensus Document on b-Adrenergic Receptor Blockers. The Task Force on Beta-Blockers of the European Society of Cardiology, Eur. Heart J. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Beta-blocker use was also associated with the female gender (p < 0.0001), emergency admission (p < 0.0001), dilated cardiomyopathy (p = 0.003), lower left ventricular ejection fraction (p = 0.02), mitral stenosis (p = 0.009), chronic kidney disease (p = 0.02), higher potassium levels (p = 0.04) and QRS duration > 120 ms (p = 0.02).”
§ Beta-Blocker-Related Atrioventricular Conduction Disorders—A Single Tertiary Referral Center Experience > 3. Results > 3.3. Patient Factors Associated with Beta-Blocker Use
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The second-degree AV block (p < 0.001) was more frequent in the BB- group, while slow ventricular response atrial fibrillation (p = 0.007), sinus pauses and sinus bradycardia (p < 0.001) were diagnosed more in the BB+ group.”
§ Beta-Blocker-Related Atrioventricular Conduction Disorders—A Single Tertiary Referral Center Experience > 3. Results > 3.2. Clinical, Echocardiographic and Biological Patient Characteristics
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Beta-blocker use was also associated with the female gender (p < 0.0001), emergency admission (p < 0.0001), dilated cardiomyopathy (p = 0.003), lower left ventricular ejection fraction (p = 0.02), mitral stenosis (p = 0.009), chronic kidney disease (p = 0.02), higher potassium levels (p = 0.04) and QRS duration > 120 ms (p = 0.02).”
§ Beta-Blocker-Related Atrioventricular Conduction Disorders—A Single Tertiary Referral Center Experience > 3. Results > 3.3. Patient Factors Associated with Beta-Blocker Use
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Beta-blocker use was also associated with the female gender (p < 0.0001), emergency admission (p < 0.0001), dilated cardiomyopathy (p = 0.003), lower left ventricular ejection fraction (p = 0.02), mitral stenosis (p = 0.009), chronic kidney disease (p = 0.02), higher potassium levels (p = 0.04) and QRS duration > 120 ms (p = 0.02).”
§ Beta-Blocker-Related Atrioventricular Conduction Disorders—A Single Tertiary Referral Center Experience > 3. Results > 3.3. Patient Factors Associated with Beta-Blocker Use
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 35 claims and every source verdict.
- Probably not a substantial claim. 2
- It may state two separate claims as one. 3
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Beta-Blocker-Related Atrioventricular Conduction Disorders—A Single Tertiary Referral Center Experience > Abstract
“Results: Of the 596 patients (mean age 73.9 ± 8.8 years, 49.2% male), 261 (43.8%) had a third-degree AV block, 92 (15.4%) had a second-degree AV block, 128 (21.5%) had slow atrial fibrillation, 93 (15.6%) had sick sinus syndrome and 21 (3.5%) had sinus bradycardia/sinus pauses.”
§ Beta-Blocker-Related Atrioventricular Conduction Disorders—A Single Tertiary Referral Center Experience > 3. Results
“The diagnoses identified were 19 (3.2%) cases of sinus disorders (bradycardia or pauses), 93 (15.6%) cases of sick sinus syndrome, 128 (21.5%) cases of slow atrial fibrillation, 261 (43.8%) cases of third-degree atrioventricular block, 92 (15.4%) cases of second-degree atrioventricular block and one (0.2%) case of first-degree atrioventricular block.”
Citations
Cites
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
2018 ESC/ESH Guidelines for the management of arterial hypertension
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy339 · Cited by 10,286
KDIGO Clinical Practice Guidelines for Acute Kidney Injury
Khwaja, A. (2012) · Nephron Clinical Practice · doi:10.1159/000339789 · Cited by 8,014 · cited 1×
“tion [14,15] and diabetes [16], were defined as per current guidelines.”
BackgroundStevens, P. E., Levin, A., & for the Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members* (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-11-201306040-00007 · Cited by 3,607
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., Drazner, M. H., Filippatos, G. S., Fonarow, G. C., Givertz, M. M., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.04.025 · Cited by 3,418
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht150 · Cited by 2,809
Authors/Task Force Members, Brignole, M., Auricchio, A., Baron-Esquivias, G., Bordachar, P., Boriani, G., Breithardt, O.-A., Cleland, J., Deharo, J.-C., Delgado, V., et al. (2013) · Europace · doi:10.1093/europace/eut206 · Cited by 1,124
6. Glycemic Targets: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s006 · Cited by 744
(2004) · European Heart Journal · doi:10.1016/j.ehj.2004.06.002 · Cited by 557
Do Women Have More Adverse Drug Reactions?
Rademaker, M. (2001) · American Journal of Clinical Dermatology · doi:10.2165/00128071-200102060-00001 · Cited by 432 · cited 1×
“Underlying these predispositions, there are several yet understudied peculiarities related to metabolism, hormonal balance and medication management [26,27].”
Background
Cited by
Ciapă, M. A., Șalaru, D. L., Stătescu, C., Sascău, R. A., & Bogdănici, C. M. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb44090272 · Cited by 37
Self-citationElectrocardiogram Features in Non-Cardiac Diseases: From Mechanisms to Practical Aspects
Ceasovschih, A., Șorodoc, V., Covanţev, S., Balta, A., Uzokov, J., Kaiser, S., Almaghraby, A. M., Lionte, C., Stătescu, C., Sascău, R. A., et al. (2024) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s445549 · Cited by 29
Self-citationDumitrof, L. C., Nedelciuc, I., Roca, M., Crișan-Dabija, R. A., Mihăescu, T., & Tinică, G. (2022) · Medicina · doi:10.3390/medicina58091182 · Cited by 4
SIDDIQUE, Y., GURUNG, S., Hemank, K. C., ADHIKARI, S., KHATRI, A., & RAI, A. (2024) · Innovare Journal of Medical Sciences · doi:10.22159/ijms.2024v12i5.51713
“deaths [13].”
Manolis, A. A., Manolis, T. A., & Manolis, A. S. (2025) · Current Vascular Pharmacology · doi:10.2174/0115701611336002241030072954
Metadata
- Authors
- Marcu, D. T. M., Adam, C. A., Dorobanțu, D.-M., Șalaru, D. L., Sascău, R. A., Balasanian, M. O., Macovei, L., Arsenescu-Georgescu, C., & Stătescu, C.
- Affiliations
- Grigore T. Popa University of Medicine and Pharmacy (RO)
- Institute of Cardiovascular Diseases “Prof. Dr. George I. M. Georgescu” Iași, 700115 Iași, Romania
- Children’s Health and Exercise Research Centre (CHERC), University of Exeter, Exeter EX1 2LU, UK
- Department of Internal Medicine, University of Medicine and Pharmacy “Grigore T. Popa” Iași, 700115 Iași, Romania
- Corresponding author
- Adam, Cristina Andreea
- ORCID
- Venue
- Medicina
- Publisher
- MDPI AG
- Published
- 2022-02-20
- Volume
- 58
- Issue
- 2
- Pages
- 320
- ISSN
- 1010-660X (ISSN-L)
- 1648-9144
- PMC
- PMC8877089
- OpenAlex
- W4214725880
- Cited by
- 6
- References
- 55
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2022: 2
- FWCI
- 0.87
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Medicina (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- UK Research and Innovation (MR/N0137941/1)
- Medical Research Council (MR/N0137941/1)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac pacing and defibrillation studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Arrhythmias and Treatments
- Keywords
- beta-blockers, atrioventricular conduction disorders, symptomatic bradycardia, complete heart block, second-degree AV block, sick sinus syndrome, sinus bradycardia, risk factors, dilated cardiomyopathy, mitral stenosis, chronic kidney disease, potassium, QRS duration
- MeSH terms
- Aged, Aged, 80 and over, Electrocardiography, Female, Humans, Male, Retrospective Studies, Sick Sinus Syndrome, Stroke Volume, Ventricular Function, Left, Tertiary Care Centers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Beta-Blocker-Related Atrioventricular Conduction Disorders—A Single Tertiary Referral Center Experience. https://app.cochat.ai/papers/10.3390/medicina58020320
- The paper
- Marcu, D. T. M., Adam, C. A., Dorobanțu, D.-M., Șalaru, D. L., Sascău, R. A., Balasanian, M. O., Macovei, L., Arsenescu-Georgescu, C., & Stătescu, C. (2022). Beta-Blocker-Related Atrioventricular Conduction Disorders—A Single Tertiary Referral Center Experience. Medicina. https://doi.org/10.3390/medicina58020320
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.